Biogen Inc. has launched the BRAVE study, a global Phase 3 clinical trial aimed at assessing the efficacy and safety of omaveloxolone in children aged 2 to under 16 years with Friedreich ataxia (FA), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback